Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
“Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)” (NCT04918186), is sponsored by CRI clinical partner the Canadian Cancer Trials Group (CCTG), and is open and actively recruiting patients to sites in Canada and, in the second half of 2022, will open sites in
CLC3E sub-study titled: An Economic Analysis of Early VS Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Companion Analysis to CCTG CLC.3 / SWOG 1925 Randomized
The Allan Blair Cancer Centre IND234 trial team has been awarded the 2022 CCTG IND Team Award for performance in trial accrual, local activation timelines, and compliance metrics, team performance.
Dr. Jonathan Loree has been recognized for his Phase III research contributions with the CCTG 2022 Dr. Ralph Meyer Phase III Young Investigator Award.
CCTG congratulates BC Cancer Vancouver GCC1 Trial Team whose work was recognized with the 2022 CCTG Phase III Team Award, for performance in trial accrual, local activation timelines, compliance metrics and team performance.
The Dr. Joseph Pater Founder’s Award has been presented to Dr. Warren Mason, MD, FRCPC for his excellence in clinical trials research, leadership and his body of work that has contributed to significant advances in the understanding, diagnosis, treatment, cure, and prevention of cancer.
CCTG congratulates the Hotel-Dieu du Quebec MA39 trial team for their CCTG Phase III Team Award presented at the CCTG 2022 Spring Meeting.
The award is given to trial teams from member centres for performance in trial accrual, local activation timelines, compliance metrics and team performance. The team includes, Alexandre Villeneuve-Gauthier, Josee Allard, Dr. Valerie Theberge, Sophie Pouliot, Isabelle Desrosiers.